Ultragenyx wins a blockbuster OK for its leading rare disease drug burosumab -- priced at $200,000
Ultragenyx $RARE has won the big FDA approval they were looking for.
The biotech — allied with Kyowa Hakko Kirin — reported Tuesday afternoon that the agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
